Sector News

Perrigo rejects Mylan’s higher bid

April 30, 2015
Life sciences
Perrigo is still standing strong against Mylan’s takeover attempt, rejecting the latest offer of $75 in cash and 2.3 shares for every share of Perrigo on the basis that is undervalues the business.
 
The Dublin, Ireland-based group is arguing that the new offer remains under Mylan’s original bid value of $205 per share, because the latter’s stock was subsequently inflated by speculation over Teva’s interest in acquiring the firm.
 
“Today’s announcement from Mylan continues to propose a price lower than the previously rejected proposal,” Perrigo said, insisting that “based on Mylan’s unaffected price of $55.31 per share on March 10, 2015, the last day of trading prior to widespread public speculation that Teva was considering an offer for Mylan, the value of the revised Offer is $202.20 per Perrigo share”.
 
Mylan is desperate to complete its plans to acquire Perrigo because that would protect it from being snapped up by Teva.
 
Pen wars
Meanwhile the growing spat between Teva and Mylan chiefs continues to be aired in public. Mylan head Robert Coury sent Teva chief Erez Vigodman a hugely critical letter outlining his objection to the move, highlighting the latter’s “poor record of delivering sustainable shareholder value”.
 
Now Teva has retaliated with a responding letter, slamming Coury for his “fundamentally distorted picture” of Teva and asserting that “stakeholders do not support, or benefit from, mudslinging, mischaracterization, rehashing of history or selective presentation of facts”. 
 
“Instead, I would prefer to return the dialogue to the significant value creation opportunity that a combination of Teva and Mylan represents,” Vigodman wrote. In a further dig, he notes “I fully agree with you that it would have been preferable to have engaged in a private discussion to explore this transaction. However, you left us no choice but to make our proposal public after you publicly rejected a potential offer before it had even been made”.
 
By Selina McKee
 
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]